MoonLake Immunotherapeutics Seeks BLA for Sonelokimab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2025
0mins
Should l Buy MLTX?
MoonLake Immunotherapeutics' stock surged by 21.20% as it reached a 20-day high, reflecting strong investor interest amid positive market conditions.
The surge is attributed to MoonLake's Type B meeting outcome with the FDA, confirming that the BLA submission for Sonelokimab can be based on existing trial data, eliminating the need for additional clinical trials. This significant development accelerates the path to market for Sonelokimab, which has shown promising results in treating hidradenitis suppurativa (HS), a condition affecting approximately 2% of the population. The FDA's feedback enhances MoonLake's competitive position in the biopharmaceutical sector, potentially leading to substantial market opportunities.
This positive news not only boosts investor confidence but also positions MoonLake favorably for future growth, especially with plans to submit the BLA in H2 2026 and an upcoming Investor Day to discuss further developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 16.870
Low
5.00
Averages
24.10
High
45.00
Current: 16.870
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rothschild & Co Upgrades MoonLake to Buy on Approval Path Clarity
- Rating Upgrade: Rothschild & Co has upgraded MoonLake Immunotherapeutics (MLTX) from Neutral to Buy, primarily due to a clearer approval path for its lead candidate sonelokimab, indicating the company's potential in the biotech sector.
- Regulatory Hurdles Eased: Analyst Qize Ding noted that while regulatory filings for sonelokimab are incomplete, the FDA has indicated that no additional trials are necessary based on existing Phase 2 and 3 data, suggesting that the biggest regulatory hurdle has been cleared, which could expedite the approval process.
- Price Target Increase: Ding raised the price target for MLTX from $12 to $40 per share, reflecting strong confidence in sonelokimab, which is expected to have an overall profile similar to the best-in-class approved therapy for hidradenitis suppurativa, indicating optimistic market expectations for the drug.
- Sales Forecast Boost: The analyst also increased peak sales estimates for sonelokimab from $2.7 billion to $3.2 billion, surpassing the consensus estimate of $2.1 billion, highlighting the drug's continued attractiveness for large biopharma companies and its potential for significant revenue growth.
See More
Cormorant Asset Management Increases Stake in MoonLake Immunotherapeutics
- Share Acquisition: Cormorant Asset Management disclosed a purchase of 2,361,260 shares of MoonLake Immunotherapeutics in its SEC filing on February 17, 2026, with an estimated transaction value of $27.86 million, indicating confidence in the company.
- Increased Ownership: This acquisition raised MoonLake's stake to 2.65% of Cormorant's reportable U.S. equities, highlighting its significance in the portfolio despite the company's stock price dropping nearly 60% over the past year.
- Financial Overview: MoonLake reported $56 million in R&D expenses and $9.2 million in administrative costs for Q4, ending the year with approximately $394 million in cash and equivalents, sufficient to fund operations into the second half of next year.
- Clinical Developments: Despite fluctuations in the clinical trial results for its lead drug Sonelokimab, early data shows promise in treating axial spondyloarthritis, and if later-stage studies confirm these findings, it could capture a share in the rapidly expanding immunology market.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
MoonLake Immunotherapeutics Receives Upgraded Rating
- Rating Upgrade: MoonLake Immunotherapeutics (MLTX) has received an 'overweight' rating, reflecting analysts' optimistic expectations for its future performance, which may attract more investor interest.
- Price Target Set: The average price target is set at $22, indicating market recognition of the company's growth potential, which could drive the stock price towards this target.
- Market Reaction: The upgrade in rating and price target may enhance investor confidence, potentially increasing trading volume and market activity for MLTX, thereby strengthening its competitiveness in the biotechnology sector.
- Investor Attention: With the rating upgrade, MLTX is likely to attract more institutional investors, further driving its stock price up and enhancing the company's visibility within the industry.
See More
Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading
- Significant Price Surge: Vanda Pharmaceuticals' shares jumped 33% in pre-market trading to $7.65, indicating strong market confidence in its future performance, which may attract more investor interest.
- Positive Market Reaction: This price surge reflects optimistic expectations from investors regarding Vanda's potential growth opportunities, potentially facilitating further development in the biopharmaceutical sector.
- Increased Trading Activity: With the notable price increase, Vanda's trading volume is likely to rise, providing the company with enhanced liquidity to support its R&D and market expansion plans.
- Improved Investor Sentiment: The rise in Vanda's stock price may enhance overall investor sentiment, particularly in the biopharmaceutical industry, further boosting the performance of related stocks.
See More
Trump Announces Global Tariff Increase to 15%
- Tariff Increase Impact: President Trump announced a rise in global tariffs from 10% to 15%, following a Supreme Court ruling deeming the previous rate ‘anti-American’, which may exacerbate market uncertainty and affect investor confidence.
- Market Reaction: U.S. stock futures sharply declined on Monday morning, with Nasdaq futures down 0.6%, S&P 500 and Dow futures each falling 0.5%, and Russell 2000 futures nearly down 1%, indicating investor concerns over tariff hikes and geopolitical tensions.
- Retail Sentiment Shift: Retail sentiment towards the SPDR S&P 500 ETF (SPY) shifted from ‘neutral’ to ‘bearish’, while the Invesco QQQ Trust (QQQ) ETF remained ‘bearish’ amid high trading volumes, reflecting a pessimistic outlook on future market performance.
- Economic Data Watch: Investors will monitor factory orders data set to be released at 10:00 AM ET today, along with commentary from Fed Governor Christopher Wallace, as these insights could further influence market sentiment and investment strategies.
See More
Rothschild & Co Upgrades MoonLake to Buy on Approval Path Clarity
- Rating Upgrade: Rothschild & Co has upgraded MoonLake Immunotherapeutics (MLTX) from Neutral to Buy, primarily due to a clearer approval path for its lead candidate sonelokimab, indicating the company's potential in the biotech sector.
- Regulatory Hurdles Eased: Analyst Qize Ding noted that while regulatory filings for sonelokimab are incomplete, the FDA has indicated that no additional trials are necessary based on existing Phase 2 and 3 data, suggesting that the biggest regulatory hurdle has been cleared, which could expedite the approval process.
- Price Target Increase: Ding raised the price target for MLTX from $12 to $40 per share, reflecting strong confidence in sonelokimab, which is expected to have an overall profile similar to the best-in-class approved therapy for hidradenitis suppurativa, indicating optimistic market expectations for the drug.
- Sales Forecast Boost: The analyst also increased peak sales estimates for sonelokimab from $2.7 billion to $3.2 billion, surpassing the consensus estimate of $2.1 billion, highlighting the drug's continued attractiveness for large biopharma companies and its potential for significant revenue growth.
See More
Cormorant Asset Management Increases Stake in MoonLake Immunotherapeutics
- Share Acquisition: Cormorant Asset Management disclosed a purchase of 2,361,260 shares of MoonLake Immunotherapeutics in its SEC filing on February 17, 2026, with an estimated transaction value of $27.86 million, indicating confidence in the company.
- Increased Ownership: This acquisition raised MoonLake's stake to 2.65% of Cormorant's reportable U.S. equities, highlighting its significance in the portfolio despite the company's stock price dropping nearly 60% over the past year.
- Financial Overview: MoonLake reported $56 million in R&D expenses and $9.2 million in administrative costs for Q4, ending the year with approximately $394 million in cash and equivalents, sufficient to fund operations into the second half of next year.
- Clinical Developments: Despite fluctuations in the clinical trial results for its lead drug Sonelokimab, early data shows promise in treating axial spondyloarthritis, and if later-stage studies confirm these findings, it could capture a share in the rapidly expanding immunology market.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
MoonLake Immunotherapeutics Receives Upgraded Rating
- Rating Upgrade: MoonLake Immunotherapeutics (MLTX) has received an 'overweight' rating, reflecting analysts' optimistic expectations for its future performance, which may attract more investor interest.
- Price Target Set: The average price target is set at $22, indicating market recognition of the company's growth potential, which could drive the stock price towards this target.
- Market Reaction: The upgrade in rating and price target may enhance investor confidence, potentially increasing trading volume and market activity for MLTX, thereby strengthening its competitiveness in the biotechnology sector.
- Investor Attention: With the rating upgrade, MLTX is likely to attract more institutional investors, further driving its stock price up and enhancing the company's visibility within the industry.
See More
Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading
- Significant Price Surge: Vanda Pharmaceuticals' shares jumped 33% in pre-market trading to $7.65, indicating strong market confidence in its future performance, which may attract more investor interest.
- Positive Market Reaction: This price surge reflects optimistic expectations from investors regarding Vanda's potential growth opportunities, potentially facilitating further development in the biopharmaceutical sector.
- Increased Trading Activity: With the notable price increase, Vanda's trading volume is likely to rise, providing the company with enhanced liquidity to support its R&D and market expansion plans.
- Improved Investor Sentiment: The rise in Vanda's stock price may enhance overall investor sentiment, particularly in the biopharmaceutical industry, further boosting the performance of related stocks.
See More
Trump Announces Global Tariff Increase to 15%
- Tariff Increase Impact: President Trump announced a rise in global tariffs from 10% to 15%, following a Supreme Court ruling deeming the previous rate ‘anti-American’, which may exacerbate market uncertainty and affect investor confidence.
- Market Reaction: U.S. stock futures sharply declined on Monday morning, with Nasdaq futures down 0.6%, S&P 500 and Dow futures each falling 0.5%, and Russell 2000 futures nearly down 1%, indicating investor concerns over tariff hikes and geopolitical tensions.
- Retail Sentiment Shift: Retail sentiment towards the SPDR S&P 500 ETF (SPY) shifted from ‘neutral’ to ‘bearish’, while the Invesco QQQ Trust (QQQ) ETF remained ‘bearish’ amid high trading volumes, reflecting a pessimistic outlook on future market performance.
- Economic Data Watch: Investors will monitor factory orders data set to be released at 10:00 AM ET today, along with commentary from Fed Governor Christopher Wallace, as these insights could further influence market sentiment and investment strategies.
See More
